A panel of outside advisers to the U.S. health regulator on Wednesday voted against authorizing Veru Inc's drug for treating high-risk patients hospitalized with COVID-19, citing multiple concerns over efficacy and safety data being based on a small trial.
Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
drug for treating high-risk patients hospitalized with COVID-19, citing multiple concerns over efficacy and safety data being based on a small trial. "Even though is impressive for a new molecular entity - it has no direct evidence to support the antiviral activity," said panel member Susanne May, who voted against authorization of the drug.
While data shows sabizabulin can also produce antiviral and anti-inflammatory responses, the U.S. Food and Drug Administration staff reviewers have said its effects against COVID-19 are uncertain.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Illinois reports 1,480 new COVID cases, 0 new deathsIllinois reported 1,480 new COVID cases and 0 new deaths Wednesday. Chicago's top doc is warning that low booster rates could lead to a new variant.
Les mer »
Poverty drops in California but only because of child tax credit, COVID relief fundsIf you haven’t filed for a child tax credit, now’s the time to do it. A deadline approaches.
Les mer »
China sees violent protests against COVID restrictions, and U.S. cases have been risingSeven people in northeastern China were arrested after a clash between residents and police enforcing COVID quarantine restrictions, the Associated Press reported.
Les mer »